metabolism and drug interactions

SECTION 1: Learning Outcomes

  • Outline the two phases of drug metabolism in the liver.

  • Describe the importance of the CYP450 enzyme family in metabolism.

  • Give examples of drugs that are enzyme inhibitors and inducers.

  • Appreciate how natural products (e.g., grapefruit) and other drugs can affect drug metabolism.

  • Explain pharmacogenomics and describe how genetic differences affect individual responses to drugs.

  • Analyze the case study of paracetamol toxicity: how metabolism and genetics influence toxicity.

SECTION 2: The ADME Process and Metabolism Overview

  • ADME: Absorption, Distribution, Metabolism, Excretion.

  • Metabolism = Biotransformation:

    • An enzymatic process that converts non-polar, lipophilic drugs into more polar, hydrophilic compounds for excretion.

  • Purpose of Metabolism:

    1. Essential for elimination of drugs/xenobiotics and termination of their biological activity.

    2. Detoxifies drugs.

    3. Activates prodrugs.

    4. Facilitates drug clearance.

  • Primary Site: The liver is the major organ. Secondary sites: kidneys, lungs, intestines, skin.

  • Principle: Lipid-soluble drugs enter hepatocytes for metabolism. Water-soluble drugs tend to be excreted unchanged.

SECTION 3: The Two Phases of Hepatic Metabolism

3.1 Phase I Reactions (Functionalisation)

  • Goal: Introduce or unmask a functional group (-OH, -NH₂, -SH) to make the drug more polar.

  • Reaction Types: Oxidation, Reduction, Hydroxylation.

  • Key Enzymes: Primarily the Cytochrome P450 (CYP) monooxygenase system.

  • Outcome: Usually results in loss of pharmacological activity. Sometimes the metabolite can be:

    • Equally or more active (e.g., active metabolite of a prodrug).

    • Toxic (e.g., NAPQI from paracetamol).

3.2 Phase II Reactions (Conjugation)

  • Goal: Attach a large, polar endogenous molecule to the drug or its Phase I metabolite.

  • Conjugation Substrates: Glucuronic acid, sulfate, acetate, glutathione, amino acids.

  • Reaction Types: Glucuronidation, sulfation, acetylation, glutathione conjugation.

  • Outcome: Creates a highly polar compound that is rapidly excreted in urine and feces.

SECTION 4: The Cytochrome P450 (CYP450) System

  • Description: A superfamily of heme-containing proteins crucial for metabolizing drugs, environmental chemicals, and other xenobiotics.

  • Scale: ~1000 known CYPs; about 50 are active in humans.

  • Nomenclature (e.g., CYP2D6*4):

    • CYP: Root.

    • Number (2): Designates the family.

    • Letter (D): Designates the subfamily.

    • Number (6): Identifies the specific enzyme.

    • Asterisk & Number (*4): Identifies a specific genetic allele/variant.

  • Key Families in Humans: Only 18 families are involved in drug metabolism. Key players include CYP1, CYP2, CYP3.

  • Dominant Enzyme: CYP3A4 metabolizes approximately ~50% of all marketed drugs.

    • (Visual: A pie chart shows the contribution of different CYP enzymes to the metabolism of 403 drugs. CYP3A4 is the largest slice.)

  • Examples of Substrates:

    • CYP3A4: Clarithromycin, cyclosporine, carbamazepine.

    • CYP2D6: Amitriptyline, codeine, haloperidol.

    • CYP2C9: Diclofenac, ibuprofen, warfarin.

    • CYP1A2: Paracetamol (partial).

SECTION 5: First-Pass Metabolism

  • Definition: Inactivation or metabolism of a drug in the GI tract, gut wall, or liver before it reaches systemic circulation.

  • Consequence: Leads to reduced drug concentration at the site of action.

  • Clinical Example – Propranolol: Undergoes extensive first-pass metabolism, explaining a 20-fold difference between effective IV and oral doses.

  • Bypassing First-Pass Metabolism: Use alternative routes:

    • Sublingual/Buccal/Transdermal (e.g., Glyceryl Trinitrate).

    • Rectal (e.g., Morphine).

    • Intravenous.

  • Grapefruit Juice Interaction: Inhibits intestinal CYP3A4, increasing the bioavailability (and thus toxicity risk) of drugs like Felodipine, Terfenadine, Ciclosporin. This interaction has been fatal in some cases.

SECTION 6: Factors Influencing Drug Metabolism

6.1 Food/Drug Interactions (Enzyme Inducers & Inhibitors)

  • Enzyme Inducers: Increase enzyme activity, leading to faster drug metabolism, reduced drug potency, and potential therapeutic failure.

    • Examples: St. John's Wort (induces CYP3A4), Barbiturates, Carbamazepine, Phenytoin, Rifampicin, Chronic Ethanol.

    • Affected Drugs: Cyclosporine, warfarin, oral contraceptives, atorvastatin.

  • Enzyme Inhibitors: Decrease enzyme activity, leading to slower drug metabolism, increased and prolonged drug action, and risk of toxicity.

    • Examples: Grapefruit Juice (inhibits CYP3A4), Cimetidine, Erythromycin, Sodium Valproate, Quinolones.

    • Special Case – Grapefruit & Uptake Transporters: Grapefruit juice can reduce the bioavailability of drugs like Aliskiren and Bilastine by inhibiting the OATP1A2 uptake transporter, not CYP enzymes.

6.2 Age

  • Neonates/Infants (<1-2 years): Microsomal enzyme systems (especially UGT for glucuronidation) are not fully developed. Drugs are metabolized slowly, increasing toxicity risk.

  • Elderly: Reduced liver size, hepatic blood flow, and enzyme activity (especially CYP3A) lead to decreased drug metabolism. Polypharmacy exacerbates risks.

6.3 Genetic Polymorphisms (Pharmacogenomics)

  • Definition (Pharmacogenomics): The study of how genes affect a person's response to drugs. Aims to customize therapy based on genetic profiles.

  • Impact: Genetic variations (polymorphisms) in genes encoding drug-metabolizing enzymes create different "metabolizer phenotypes."

  • CYP450 Phenotypes:

    • UM: Ultrarapid Metabolizer (very fast metabolism).

    • EM: Extensive Metabolizer (normal metabolism).

    • IM: Intermediate Metabolizer (reduced metabolism).

    • PM: Poor Metabolizer (very slow metabolism).

  • Key Examples of Genetic Variability:

    • CYP2D6 Polymorphisms: Affect metabolism of codeine (PMs get no analgesia; UMs get toxicity), antidepressants, antipsychotics.

    • CYP2C9 & VKORC1: Critical for warfarin dosing. Genetic testing guides safe and effective dosing.

    • N-Acetylation Polymorphism: Creates "rapid" vs. "slow" acetylators for drugs like isoniazid, hydralazine, procainamide.

    • Pseudocholinesterase Deficiency: Leads to prolonged apnea with succinylcholine.

    • G6PD Deficiency: Risk of hemolysis with drugs like aspirin, quinine, some sulfonamides.

SECTION 7: Personalised (Precision) Medicine

  • Concept: Tailoring medical treatment to individual patient characteristics, especially genetic makeup.

  • Goals: Enhance efficacy, minimize adverse effects, optimize dosing.

  • Tools: Genetic testing (e.g., for CYP variants, SLCO1B1 for statin-induced myopathy).

  • Examples in Practice:

    • Clopidogrel: Inactive prodrug activated by CYP2C19. Poor metabolizers (especially common in East Asian populations) get little antiplatelet effect, increasing risk of stroke/heart attack. (Notable lawsuit: Hawaii vs. Bristol Myers Squibb/Sanofi).

    • PPI Interaction: Omeprazole inhibits CYP2C19, reducing clopidogrel activation. Pantoprazole/Lansoprazole are preferred if co-administration is needed.

    • Statins: Testing for SLCO1B1 gene variant identifies patients at high risk for statin-induced myopathy.

SECTION 8: Case Study – Paracetamol (Acetaminophen) Toxicity

8.1 Normal Metabolism:

  1. Major Safe Pathways (Phase II, ~85%):

    • Glucuronidation (45-55%).

    • Sulfation (20-30%).

  2. Minor Toxic Pathway (Phase I, <15%):

    • Oxidation by CYP2E1 (and others) forms the highly reactive, toxic metabolite N-acetyl-p-benzoquinone imine (NAPQI).

    • NAPQI is immediately detoxified by conjugation with glutathione (a Phase II-like reaction) and excreted.

8.2 Toxicity Mechanism (Overdose):

  • Saturation of the safe glucuronidation/sulfation pathways.

  • Shunting of more paracetamol down the CYP2E1 pathway → excessive NAPQI production.

  • Depletion of hepatic glutathione stores.

  • Unquenched NAPQI binds to liver cell proteins, causing oxidative damage, centrilobular hepatic necrosis, and potentially liver failure.

8.3 Risk Factors (Increase NAPQI or Deplete Glutathione):

  • Chronic Alcohol Use: Induces CYP2E1, increasing NAPQI production.

  • Fasting/Malnutrition: Depletes glutathione stores.

  • Pre-existing Liver Disease.

  • Genetic Factors: Polymorphisms in CYP2E1 (higher activity) or glutathione S-transferase (GST) genes (lower detox capacity).

8.4 Treatment:

  • Antidote: N-Acetylcysteine (NAC).

  • Mechanism: Replenishes glutathione stores, allowing detoxification of NAPQI.

SECTION 9: Alcohol's Impact on Drug Metabolism

  • Acute Intake: Inhibits CYP enzymes (e.g., competes for CYP2E1), leading to decreased metabolism and increased drug levels/toxicity (e.g., of warfarin).

  • Chronic Intake: Induces CYP2E1, leading to increased metabolism. This is particularly dangerous for paracetamol (↑ NAPQI) and can reduce efficacy of other drugs.

  • Liver Damage: Chronic use causes cirrhosis, severely impairing all metabolic functions.

  • Enzyme Competition: Alcohol and drugs compete for ADH and ALDH.

  • Disulfiram-like Reaction: Drugs like metronidazole inhibit aldehyde dehydrogenase, causing acetaldehyde accumulation if alcohol is consumed, leading to vomiting, flushing, and tachycardia.

SECTION 10: Summary & Conclusions

  • Drug metabolism is a biochemical process primarily in the liver for elimination and detoxification.

  • It occurs in two phases (I: functionalization, II: conjugation).

  • The CYP450 enzyme family is critically important, with CYP3A4 being the most significant.

  • Drug metabolism can be altered by:

    • Enzyme inducers (speed up metabolism).

    • Enzyme inhibitors (slow down metabolism).

    • Age (very young and old have reduced capacity).

    • Genetic polymorphisms (creating poor, intermediate, extensive, or ultrarapid metabolizers).

  • These factors necessitate dose adjustments and underpin the move towards personalized (precision) medicine.

  • The paracetamol case study exemplifies how understanding metabolic pathways and genetics is crucial for predicting and managing toxicity.

QUESTIONS:

Section 1: Single Best Answer Questions

Q1:

Which phase of drug metabolism involves conjugation with glucuronic acid or sulfate to increase polarity for excretion?
A) Phase 0
B) Phase I
C) Phase II
D) Phase III

Answer:

C - Phase II
Rationale: Phase II reactions (conjugation) attach polar endogenous molecules like glucuronate or sulfate to drugs or their Phase I metabolites. Phase I involves oxidation/reduction; Phases 0 and III refer to transport processes.

Q2:

A patient taking warfarin starts St. John's Wort. What is the likely effect on warfarin therapy?
A) Increased INR and bleeding risk
B) Decreased INR and reduced anticoagulation
C) No effect on warfarin
D) Direct pharmacodynamic interaction

Answer:

B - Decreased INR and reduced anticoagulation
Rationale: St. John's Wort induces CYP2C9 (and possibly CYP3A4), increasing warfarin metabolism → lower plasma levels → reduced anticoagulation. Requires closer INR monitoring and possible dose increase.

Q3:

Which cytochrome P450 enzyme is responsible for metabolizing approximately 50% of all marketed drugs?
A) CYP2D6
B) CYP2C9
C) CYP3A4
D) CYP1A2

Answer:

C - CYP3A4
Rationale: CYP3A4 is the most abundant hepatic and intestinal CYP enzyme, involved in metabolizing ~50% of drugs. It has broad substrate specificity and is highly susceptible to inhibition/induction.

Q4:

In paracetamol overdose, toxicity occurs primarily due to:
A) Saturation of glucuronidation pathways
B) Direct hepatocyte damage by unmetabolized paracetamol
C) Excessive NAPQI formation overwhelming glutathione stores
D) Inhibition of CYP2E1 enzyme

Answer:

C - Excessive NAPQI formation overwhelming glutathione stores
Rationale: Normally, <15% of paracetamol is oxidized by CYP2E1 to NAPQI, which is detoxified by glutathione. In overdose, safe pathways saturate, more NAPQI forms, glutathione depletes → NAPQI binds hepatocyte proteins → necrosis.

Section 2: Extended Matching Questions

Theme: Drug Metabolism Effects

Options:
A) Enzyme inducer
B) Enzyme inhibitor
C) Prodrug requiring activation
D) Substrate for polymorphic enzyme
E) Bypasses first-pass metabolism

Q1:

Codeine metabolized to morphine by CYP2D6

Answer:

C - Prodrug activated via CYP2D6 (PMs get no effect, UMs get toxicity).

Q2)

Rifampicin, increasing metabolism of oral contraceptives

Answer:

A - Potent inducer of multiple CYP enzymes (3A4, 2C9).

Q3)

Clopidogrel efficacy reduced in CYP2C19 poor metabolizers

Answer:

D - CYP2C19 polymorphism affects activation (Asian populations high PM prevalence).

Q4)

Sublingual nitroglycerin for acute angina

Answer:

E - Avoids first-pass hepatic metabolism for rapid effect.

Theme: Pharmacogenomic Phenotypes

Options:
A) Ultrarapid metabolizer (UM)
B) Extensive metabolizer (EM)
C) Intermediate metabolizer (IM)
D) Poor metabolizer (PM)

Q1:

Standard dose of drug produces subtherapeutic effect; may need higher dose

Answer:

A - UM rapidly metabolizes drug → lower exposure.

Q2)

Standard dose causes toxicity due to drug accumulation

Answer:

D - PM metabolizes slowly → higher exposure.

Q3)

Most common phenotype; standard dosing usually appropriate

Answer:

B - EM represents "normal" metabolism.

Q4)

May require dose reduction but standard dosing sometimes adequate

Answer:

C - IM has reduced but not absent enzyme activity.

Section 3: Clinical Scenario - Drug Interactions

Scenario: Mrs. Johnson, 72, stabilized on warfarin 4mg daily (INR 2.5). She develops bronchitis and is prescribed clarithromycin 500mg BD for 7 days. She also takes atorvastatin 40mg nocte. She mentions she's been drinking grapefruit juice daily for "heart health."

Q: Analyze the potential drug interactions, mechanisms, clinical risks, and management plan.

In-depth Answer:

INTERACTION ANALYSIS:

1. Clarithromycin + Warfarin:

  • Mechanism: Clarithromycin is a potent CYP3A4 inhibitor (also inhibits CYP2C9 to lesser extent)

  • Effect on warfarin: Reduced metabolism of S-warfarin (CYP2C9 substrate) → increased plasma levels → elevated INR, bleeding risk

  • Timing: INR rises within 2-3 days of starting clarithromycin

  • Severity: High risk (macrolides among highest risk antibiotics for warfarin interaction)

2. Clarithromycin + Atorvastatin:

  • Mechanism: CYP3A4 inhibition reduces atorvastatin metabolism

  • Effect: Increased atorvastatin exposure 4-6 fold → increased myopathy/rhabdomyolysis risk

  • Severity: Moderate-high (statin dose >20mg increases risk)

3. Grapefruit Juice + Atorvastatin:

  • Mechanism: Grapefruit inhibits intestinal CYP3A4 and OATP transporters

  • Effect: Increases atorvastatin bioavailability up to 3-fold (additive to clarithromycin effect)

  • Severity: Moderate (chronic consumption more problematic than single glass)

4. Grapefruit Juice + Warfarin:

  • Mechanism: Minimal direct effect (warfarin not CYP3A4 substrate)

  • Potential: Vitamin K content could affect INR

  • Severity: Low

CUMULATIVE RISK: Triple interaction (clarithromycin + grapefruit + atorvastatin) dramatically increases statin toxicity risk. Clarithromycin + warfarin increases bleeding risk.

MANAGEMENT PLAN:

Immediate actions (Day 1):

  1. Stop grapefruit juice immediately (counsel on other citrus interactions)

  2. Hold atorvastatin for 7-10 days (duration of clarithromycin + washout)

  3. Warfarin dose reduction: Reduce to 3mg daily (25% reduction empirically)

  4. INR monitoring: Check INR in 3 days, then every 2-3 days during antibiotic course

Alternative antibiotic considerations:

  • Preferred: Amoxicillin or doxycycline (minimal CYP interactions)

  • If macrolide needed: Azithromycin (less CYP inhibition than clarithromycin)

  • In this case: Switch to amoxicillin 500mg TDS if appropriate for bronchitis

Patient education:

  • "Grapefruit affects many medications - avoid entirely while on these drugs"

  • "Report muscle pain, weakness, brown urine (statin toxicity)"

  • "Watch for bruising, bleeding gums, dark stools (warfarin toxicity)"

  • "Don't restart atorvastatin until 3 days after finishing antibiotic"

Monitoring schedule:

  • Day 3: INR, CK (creatine kinase) if muscle symptoms

  • Day 7: INR (end of antibiotic)

  • Day 10: Restart atorvastatin, check CK if symptomatic

  • Weekly INR until stable for 2 readings

Documentation:

  • Interaction risks discussed with patient

  • Multifactorial INR elevation likely if occurs

  • Plan for future: Flag "grapefruit avoidance" and "macrolide caution" in records

PREVENTION FOR FUTURE:

  • Pharmacist review of all new medications

  • Patient medication card listing interactions

  • Consider switching to direct oral anticoagulant (DOAC) if appropriate (fewer drug interactions)

SPECIAL CONSIDERATIONS:

  • Age 72: Reduced hepatic metabolism, increased susceptibility

  • Polypharmacy: Regular medication review needed

  • Dietary habits: Full dietary assessment for other interactions

Section 4: Pharmacogenomics Case - CYP2D6 & Codeine

Scenario: A breastfeeding mother is prescribed codeine for postpartum pain. She is a CYP2D6 ultrarapid metabolizer (UM). Her newborn develops sedation and respiratory depression.

Q: Explain the pharmacogenomic mechanism, risks across different metabolizer phenotypes, and alternative pain management strategies.

In-depth Answer:

PHARMACOGENOMIC MECHANISM:

Codeine as prodrug:

  • Codeine → (CYP2D6) → morphine (active analgesic)

  • Minor pathways: CYP3A4 to norcodeine, UGT2B7 to codeine-6-glucuronide

CYP2D6 polymorphism spectrum:

  • PM (Poor): 5-10% Caucasians, higher in Asians → little morphine → inadequate pain relief

  • IM (Intermediate): Reduced activity → variable response

  • EM (Extensive): ~70-80% population → standard response

  • UM (Ultrarapid): 1-10% population (higher in North Africans, Middle Eastern) → rapid, extensive conversion → morphine toxicity

THIS CASE: Mother is UM → produces excessive morphine → passes to breast milk → neonatal opioid toxicity

RISK FACTORS AGGRAVATING TOXICITY:

  1. Neonatal factors: Immature blood-brain barrier, renal clearance

  2. Breastfeeding timing: Morphine peaks in milk 1-2 hours post-dose

  3. Concurrent medications: CYP2D6 inhibitors could convert UM to functional PM

CLINICAL PRESENTATION IN NEWBORN:

  • Sedation, poor feeding

  • Respiratory depression (breathing <40/min, apnea)

  • Constipation

  • In severe cases: CNS depression, hypotonia

PHENOTYPE-SPECIFIC MANAGEMENT:

For UM patients (like this mother):

  • Avoid codeine entirely - contraindicated

  • Alternative opioids: Morphine or hydromorphone (not prodrugs)

  • Non-opioid options: NSAIDs (ibuprofen safe while breastfeeding), paracetamol

  • If codeine given accidentally: Monitor for toxicity, consider naloxone

For PM patients:

  • Codeine ineffective - use alternative analgesia

  • Document PM status to prevent future codeine use

For EM/IM patients:

  • Standard dosing with monitoring

  • Watch for side effects, especially with higher doses

BREASTFEEDING RECOMMENDATIONS:

  • General: Short-term, low-dose codeine may be okay for EM mothers with monitoring

  • UM mothers: Absolute contraindication for codeine while breastfeeding

  • Monitoring baby: Alertness, feeding patterns, respiratory rate

  • Timing: Feed before dose, avoid breastfeeding at peak milk levels (2-4h post-dose)

GENETIC TESTING CONSIDERATIONS:

  • When to test: Prior to opioid therapy, family history of adverse reactions, specific ethnic backgrounds

  • Cost-effectiveness: Increasingly justified given toxicity risks

  • Testing methods: PCR-based genotyping for common CYP2D6 alleles

ALTERNATIVE PAIN MANAGEMENT REGIMEN:

  1. First-line: Ibuprofen 400mg TDS + paracetamol 1g QDS (both breastfeeding-safe)

  2. If severe pain: Morphine immediate-release 5-10mg Q4H PRN

  3. Non-pharmacological: Positioning, relaxation techniques

  4. Avoid: Tramadol (also CYP2D6 dependent), dihydrocodeine

DOCUMENTATION & REPORTING:

  • Document CYP2D6 status in medical record

  • Report adverse event to pharmacovigilance agency

  • Counsel on genetic implications for family members

PREVENTIVE STRATEGIES:

  • Hospital policies: Consider CYP2D6 testing before postoperative codeine

  • Electronic alerts: Flag UM status in prescribing systems

  • Patient education: "Codeine safety depends on your genetics"

BROADER IMPLICATIONS:

  • Other CYP2D6 substrates: Antidepressants (amitriptyline), antipsychotics, tamoxifen

  • Regulatory: FDA black box warning for codeine in children after tonsillectomy

  • Ethical: Should preemptive genotyping become standard before certain prescriptions?

FOLLOW-UP FOR AFFECTED NEWBORN:

  • Pediatric assessment

  • Monitor for long-term neurodevelopmental effects

  • Genetic counseling for family

Section 5: Paracetamol Overdose & Management

Scenario: A 45-year-old man presents 24 hours after ingesting ~30g paracetamol (60 tablets) during a suicide attempt. He's a chronic alcohol user (>60 units/week) and has been fasting. Initial blood paracetamol level is 180 mg/L at 24h post-ingestion.

Q: Analyze the metabolic basis of his heightened toxicity risk, interpret the paracetamol level, and outline comprehensive management including N-acetylcysteine (NAC) rationale.

In-depth Answer:

METABOLIC RISK FACTORS:

1. Chronic Alcohol Use:

  • Induces CYP2E1 2-3 fold → increased NAPQI production

  • Depletes hepatic glutathione stores by ~50%

  • Liver damage may impair regeneration of glutathione

  • Result: Lower threshold for toxicity, more rapid progression

2. Fasting/Malnutrition:

  • Reduces hepatic glutathione by 30-50%

  • Increases CYP2E1 activity

  • Impaired sulfation pathway (requires dietary sulfate)

3. Delayed Presentation (24h):

  • May be beyond optimal NAC window (8-10h ideal)

  • Early symptoms (nausea, vomiting) may be resolving → false reassurance

  • Hepatic damage may already be established

PARACETAMOL LEVEL INTERPRETATION:

Nomogram application:

  • 180 mg/L at 24h is above 200mg/L line extended (using UK staggered/uncertain ingestion line)

  • High-risk threshold: >100 mg/L at 24h indicates need for NAC

  • This level: Indicates severe poisoning, high likelihood of hepatotoxicity without treatment

Kinetics consideration:

  • Half-life >4h suggests hepatic impairment

  • May need repeat levels if continuing absorption (co-ingestants slowing gastric emptying)

MANAGEMENT PROTOCOL:

1. Immediate Stabilization:

  • Airway/breathing/circulation: Especially if co-ingested CNS depressants

  • IV access, bloods: Paracetamol level, LFTs (ALT/AST), INR, creatinine, glucose, ABG

  • Gastro decontamination: Not indicated at 24h (absorption complete)

2. N-Acetylcysteine (NAC) Therapy:

  • Indication: ANY paracetamol level above treatment line OR ingestion >150mg/kg OR high-risk patient

  • This patient: Meets all criteria

  • Regimen (UK): 150mg/kg in 200mL 5% dextrose over 1h, then 50mg/kg in 500mL over 4h, then 100mg/kg in 1000mL over 16h (total 300mg/kg over 21h)

  • Mechanism:

    1. Precursor for glutathione synthesis (cysteine donor)

    2. Direct antioxidant effects

    3. Improves hepatic perfusion via nitric oxide

  • Even if >24h: NAC still beneficial (reduces mortality even with established hepatitis)

3. Enhanced NAC Dosing Consideration:

  • For high-risk patients, some protocols use extended or double NAC infusions

  • Given alcohol use + fasting, consider additional 100mg/kg over 12h after standard regimen

4. Supportive Care:

  • IV fluids: Dextrose-containing (prevent hypoglycemia)

  • Anti-emetics: Ondansetron if vomiting (impairs NAC tolerance)

  • Monitoring: Hourly vitals, strict fluid balance

  • Repeat LFTs/INR: 4-6 hourly initially

5. Hepatology Consult Criteria:

  • INR >2.0 at 24h or >3.0 at 48h

  • Creatinine >200 μmol/L

  • Acidosis (pH <7.3)

  • Hypoglycemia

  • Encephalopathy

  • This patient: High likelihood of meeting criteria given risk factors

SPECIFIC ALCOHOL-RELATED CONSIDERATIONS:

Alcohol Withdrawal Management:

  • Benzodiazepines: May be needed (but avoid liver-metabolized lorazepam preferred)

  • Thiamine: High-dose IV (Pabrinex) to prevent Wernicke's

  • Electrolytes: Monitor Mg²⁺, K⁺, PO₄³⁻

Altered NAC Pharmacokinetics in Alcoholics:

  • Increased volume of distribution

  • Possibly increased clearance

  • Some evidence supports higher NAC doses

LIVER FAILURE MANAGEMENT (if develops):

Medical:

  • N-acetylcysteine continued (improves outcomes even in ALF)

  • Lactulose/rifaximin if encephalopathy

  • Vitamin K for coagulopathy

  • Pressure monitoring if cerebral edema

Transplant Criteria (King's College):

  • pH <7.3 OR

  • INR >6.5 + creatinine >300 μmol/L + grade 3-4 encephalopathy

  • This patient: High risk of meeting criteria

PSYCHIATRIC ASSESSMENT:

  • After stabilization: Mental health review

  • Safety planning: Before discharge

  • Follow-up: Psychiatric outpatient appointment

PREVENTION OF FUTURE EPISODES:

  • Pack size limitations: 32 tablets OTC in UK

  • Education: Paracetamol dangers, especially with alcohol

  • Safer alternatives: Consider blister packs for at-risk patients

MONITORING TIMELINE:

First 48h:

  • LFTs/INR 6-hourly

  • Clinical assessment 2-hourly

Days 3-7:

  • Daily LFTs until peak and improving

  • Watch for late ALT rise (day 3-4 typical peak)

Follow-up:

  • Liver clinic if significant injury

  • Alcohol support services

  • Psychiatric follow-up

DOCUMENTATION ESSENTIALS:

  • Time of ingestion (best estimate)

  • Risk factors documented (alcohol, fasting)

  • Paracetamol level with time since ingestion

  • NAC start time and regimen

  • Criteria for transplant referral

  • Capacity and mental state assessment

KEY MESSAGE: In high-risk patients (alcohol, malnutrition), paracetamol toxicity occurs at lower doses, progresses more rapidly, and requires aggressive NAC therapy. Even late-presenting patients benefit from NAC.